{"name":"Precision BioSciences","slug":"precision-bio","ticker":"DTIL","exchange":"NASDAQ","domain":"precisionbiosciences.com","description":"Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary \"ARCUS\" genome editing platform.","hq":"Durham, NC","founded":0,"employees":"68","ceo":"Michael Amoroso","sector":"Gene Editing / Cell Therapy","stockPrice":6.22,"stockChange":-0.04,"stockChangePercent":-0.64,"marketCap":"$154M","metrics":{"revenue":1070000000,"revenueGrowth":5261.1,"grossMargin":100,"rdSpend":54172000,"netIncome":-45724000,"cash":115585000,"dividendYield":0,"peRatio":-1.8,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"PBCAR0191 patent cliff ($0.0B at risk)","drug":"PBCAR0191","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PBGENE-HBV","genericName":"PBGENE-HBV","slug":"pbgene-hbv","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"PBGENE-HBV","genericName":"PBGENE-HBV","slug":"pbgene-hbv","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Precision BioSciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Precision BioSciences reported its fourth quarter and full year 2023 financial results, with revenue of $13.4 million and a net loss of $43.5 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Precision BioSciences Announces Collaboration with Merck to Develop Gene-Edited CAR-T Cell Therapies","summary":"Precision BioSciences announced a collaboration with Merck to develop gene-edited CAR-T cell therapies for multiple myeloma and other cancers.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Precision BioSciences Announces Positive Interim Data from PBCAR0191 Phase 1 Clinical Trial","summary":"Precision BioSciences announced positive interim data from its PBCAR0191 Phase 1 clinical trial, with all patients achieving complete response.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-14","type":"earnings","source":"simplywall.st","summary":"Precision BioSciences (DTIL) Q4 Profit Of US$19.2m Challenges Ongoing Loss Narrative - simplywall.st","headline":"Precision BioSciences (DTIL) Q4 Profit Of US$19.2m Challenges Ongoing Loss Narrative","sentiment":"neutral"},{"date":"2026-03-12","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNcTk1MHktWlNPSGVuWFIxVEJyYzkxaXlUWEJ1LTJOdDJpLWtzMndCSDNCRHoxS3lXakFNS3ZMSjFZd3JHME54SWdHRkF4YTJ2YUU1dGhaS2lOVWJTZUIxUzVvLVhNblVZTDBzQ0cwUUlRUlpIeVdabGVMTFJvdXV2T1F5b2c4VjBTVjNMNXllQXhLTG1td2RpbWl3UXQ3YUJfVTFxTGVTQjdUenNCenEyVko4ckt3T2owdXRELV9acGhtQ2s?oc=5","date":"2026-03-02","type":"pipeline","source":"AD HOC NEWS","summary":"Precision BioSciences Stock: Can This Tiny Gene-Editing Play Survive the Cash Crunch? - AD HOC NEWS","headline":"Precision BioSciences Stock: Can This Tiny Gene-Editing Play Survive the Cash Crunch?","sentiment":"neutral"},{"date":"2026-02-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNV2NBNU52NW03VGsxQWNwRnp2eHFaTjBpa29qU0xwRjR0N3RBa212bWtVQjByYkhoM2lhbXBPOTkyREQwbjNpR24tbXpCRWNENTdobjdCX3dubF9XU1FZUkJvQnlqN3hlVENuTXljVE9nbXZaYnVNNy11WllJWG1XRTZCYW9UTzhCaDJBSlVtRDk2THRZM2VLMFdxV0tEdm1KTUN3d3ZLeHlMaGp3OVFPOXd2d2tqUQ?oc=5","date":"2025-12-29","type":"trial","source":"Seeking Alpha","summary":"Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 (NASDAQ:DTIL) - Seeking Alpha","headline":"Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 (NASDAQ:DTIL)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxQWUc4Zmk3NUNZQnd6bko1Z0p5bFZVOE05eUJfRkloYjU3S3FudkR4ZTF6R010dGZEOTV4RnVzTmo2azRIVF94N3dlV1o3V09EZHZIbUpmY25tVFlfWE1qcWFhSDI2cU1KS09Fb1hDMS1NM29VLXNLOUp3R1Bzb3B3NFBRNU04R0lENDZva0tTbnNlYkpVWHhzLVpqUUo5WUhvcFlFbV8wRUJXa0RHVlozb2J2emhNc1loWWtoQTIxQUdRMGZPcmNMRWhaZTNVYWY1b2lDRUpWTXc2Y2Z3aENjOXJhaUVCTW9sQVlV0gHwAUFVX3lxTFBxUEFVMEVCZlVUVVJLZWszWTF4N2daUlNBX2Y4VTl1QXQyY3d5blc5cHAwbXgwY3ZyU2Y0d1FGaGZXRUNVUGk5YlB2SUtoYjhMNkhIei1nYjRpVjQ0NG1rdUgzb0dvSXJLSlJSdnJMRGJkbmVSRGFiYjk2Z182OWdNbENGZWZqclR4YWNEUnFrM293b2RsaDI5R2piYTRMVDFTU29HYTFmNnh0WTlvYk1hVzVyUkQyWjhvc3hxRVR4LVFLNnVnZ0RhZTJZbG9WQnoyYW93c0ZobkRuTkxzNC1Ib0NlNVE5dFdoSXdDU1NLSw?oc=5","date":"2025-10-31","type":"pipeline","source":"simplywall.st","summary":"A great week that adds to Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns, institutional investors who own 46% must be happy - simplywall.st","headline":"A great week that adds to Precision BioSciences, Inc.'s (NASDAQ:DTIL) one-year returns, institutional investors who own ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNaUJ6dDFvRzRfNW16cEc3Q3F5bk04U2dKeDVCQ1k5T0phS2VSbGNjQmI2U2NoMGZjb3NIRk1iMjFuLUhSdUhrZTVlS2NfWnRnQ05yVnhfSmtfM2ZaU1E5U0pXNU9SR2xpaHkwa1RtSHhqZUk0R0RMRUNfckhVRk44V1E4NnRCOGxLYlprb080QlBERVJXNmpjUjNfa1NaZnVJYXJ6MUtoOFZ4MTNJbl9mdXZocnRrc3lyQk1BdzVRTVFaS1dBa18yYmFn?oc=5","date":"2025-05-08","type":"earnings","source":"Business Wire","summary":"Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025 - Business Wire","headline":"Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBSaFlfRW12U1dsdXBCYjJ0U0ZiaGJBbV83d3NRSUowci1uZWt4eGMycWQzVTVpeEg0V290WFRVYVJFcXgxSnh1X1BrdVBybWlWYXpn?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"DTIL Stock Price, News & Analysis - Stock Titan","headline":"DTIL Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQRk16TVpxbDFpRnEtUjg0QVFKSmxnUjFZdDdma0pMdnR3ZHF4YjZBYzdMTU05Nk0zM0ZsNXhITm9fempsTWZXTHlhQi1PMlBIN2g1OWVneURjWlV0b1BoNE11aGpEdS15VmhtS0NHTUNpTm1BYmIzbUhnWnBmNHRhTWFHdzNNMjN4WEptWA?oc=5","date":"2024-08-27","type":"pipeline","source":"entrepreneur.com","summary":"3 High-Potential Biotech Stocks Under $10 - entrepreneur.com","headline":"3 High-Potential Biotech Stocks Under $10","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPRTVsb252YU1udHA2dlJTc3pKTVZsRXMxcE9SQjlZYkRHaXB4TFB4ek1jVEY3WXE3LUtSNDEyemZUMl9qQmxNUHE2X2tOdUN3LVphbWRTOHVOajgwRWwtVmp1RXBfb0g0WHl1RWFCOVk3SWtaZTRiRUNpdkYyZVR3RUNRbVJUeWRDUHJmTlg0RDNtM2R5SENLdURDUmtyVUExVnlqdGY4X2ZUckp1NzAtLUlJMVc5RnA0MkVQYll5ZmtqQVJJRjg1WEcxcmp0R2JPbWZfdHBpNmxfZw?oc=5","date":"2022-05-23","type":"pipeline","source":"Precision BioSciences","summary":"Precision BioSciences Appoints Juli Blanche as Chief People Officer - Precision BioSciences","headline":"Precision BioSciences Appoints Juli Blanche as Chief People Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE02ZmwxcEdnelJmY3lkUzdlSWZ0RzlUSVlLZ3piMllNemI3SFpTN3dLbU8xaDJ5RzR5Sm5KbkdheFN5akdxblVsWnVqZ20yNnNw?oc=5","date":"2021-09-14","type":"pipeline","source":"The Motley Fool","summary":"Precision BioSciences - DTIL - Stock Price & News - The Motley Fool","headline":"Precision BioSciences - DTIL - Stock Price & News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQTEJ0Nm9uRk9QRXgxMmM3NkVyWW01VlpNMHVtWHRJLXgzeFBwYW4yT1pGUU8tVmNaUVc0QVJiaS1BUklyOE1rV2U4UG1kU1dISmhYTEt6S09LamdYOGU3VWpWdVo5dks0UjlvQnczT1FqOG5wRHBVUDZoR0VkVmtGd3JuNTZSc0gxbVJiOHVSU1JHOFdPREVLYTBWT3Ftb1NoNTFyYUgyM1pLdFVqY2dhVVl3WUYyTEQ1amhJQlI1WXh3cWtsMFdIT0NkTTl1S0xm?oc=5","date":"2021-05-28","type":"pipeline","source":"Precision BioSciences","summary":"Precision BioSciences Appoints Alex Kelly as Chief Financial Officer - Precision BioSciences","headline":"Precision BioSciences Appoints Alex Kelly as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNWEdiVTNobmNpZmNGUFowMHFJOWVnNHU1b196MDdsRjhfVkx1VDhDdVVrUTFDRjBSR0ZnMHQxU2toWEg0V194M3V4eGw3Nl9sRjBpcnI5RGhnQjNNNU9wT2NRLWptT3JOMVFQM3BSU3JkcWtVdmJUV0htSEZIaHhTRnhRUmtWZw?oc=5","date":"2021-04-01","type":"pipeline","source":"crisprmedicinenews.com","summary":"CMN Markets April 2021 (open access edition) - crisprmedicinenews.com","headline":"CMN Markets April 2021 (open access edition)","sentiment":"neutral"}],"patents":[{"drugName":"PBCAR0191","drugSlug":"pbcar0191","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Editas Medicine","CRISPR Therapeutics","Beam Therapeutics"],"therapeuticFocus":["Gene Editing","Cell Therapy"],"financials":{"source":"sec_edgar","revenue":1070000000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":1070000000,"period":"2019-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":54172000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-45724000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":154416000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":6.22,"previousClose":6.26,"fiftyTwoWeekHigh":8.82,"fiftyTwoWeekLow":3.53,"fiftyTwoWeekRange":"3.53 - 8.82","fiftyDayAverage":4.83,"twoHundredDayAverage":5.02,"beta":1.09,"enterpriseValue":68012112,"forwardPE":-1.8,"priceToBook":1.63,"priceToSales":4.49,"enterpriseToRevenue":1.99,"enterpriseToEbitda":-1.34,"pegRatio":0,"ebitda":-50680000,"ebitdaMargin":-147.9,"freeCashflow":-21974250,"operatingCashflow":-65843000,"totalDebt":28808000,"debtToEquity":31.2,"currentRatio":13.32,"returnOnAssets":-22.4,"returnOnEquity":-62.7,"analystRating":"","recommendationKey":"none","numberOfAnalysts":4,"targetMeanPrice":32,"targetHighPrice":60,"targetLowPrice":19,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":5.3,"institutionHeldPercent":64.2,"sharesOutstanding":24726695,"floatShares":19361249,"sharesShort":1396801,"shortRatio":6.4,"shortPercentOfFloat":5.7,"epsTrailing":-3.79,"epsForward":-3.4,"revenuePerShare":2.67,"bookValue":3.83,"officers":[{"age":46,"name":"Mr. Michael  Amoroso","title":"President, CEO & Director"},{"age":52,"name":"Dr. Jefferson J. Smith Ph.D.","title":"Co-Founder & Chief Research Officer"},{"age":58,"name":"Mr. John Alexander Kelly R.Ph.","title":"CFO & Principal Accounting Officer"},{"age":null,"name":"Dr. Cassie  Gorsuch Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Mr. Naresh  Tanna","title":"Chief of Staff to CEO & Head of Investor Relations"},{"age":49,"name":"Mr. Dario  Scimeca J.D.","title":"General Counsel & Secretary"},{"age":null,"name":"Ms. Juli  Blanche","title":"Chief People Officer"},{"age":null,"name":"Ms. Cindy  Atwell","title":"Chief Development & Business Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://precisionbiosciences.com","phone":"919 314 5512"}}